BRCA 1 Gene Mutation clinical trials at UC Davis
2 research studies open to eligible people
A Study of the Experimental Medicine Niraparib for Men With High Risk Prostate Cancer
open to eligible males ages 18 years and up
This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
A Study of the Experimental Medicine Rucaparib for Recurrent Non-small Cell Lung Cancer
open to all eligible people
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Sacramento, California and other locations